Aurora Investment Counsel Has $2.44 Million Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Aurora Investment Counsel lessened its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 6.6% in the 2nd quarter, HoldingsChannel reports. The fund owned 30,394 shares of the medical equipment provider’s stock after selling 2,145 shares during the quarter. Lantheus accounts for about 1.4% of Aurora Investment Counsel’s holdings, making the stock its 11th biggest holding. Aurora Investment Counsel’s holdings in Lantheus were worth $2,440,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of LNTH. Cetera Investment Advisers increased its holdings in shares of Lantheus by 34.8% in the second quarter. Cetera Investment Advisers now owns 29,592 shares of the medical equipment provider’s stock valued at $2,376,000 after purchasing an additional 7,640 shares in the last quarter. Quarry LP increased its stake in shares of Lantheus by 51.3% in the 2nd quarter. Quarry LP now owns 1,145 shares of the medical equipment provider’s stock valued at $92,000 after buying an additional 388 shares during the period. Creative Planning raised its position in shares of Lantheus by 48.5% during the second quarter. Creative Planning now owns 23,714 shares of the medical equipment provider’s stock worth $1,904,000 after acquiring an additional 7,742 shares during the last quarter. Mackenzie Financial Corp lifted its stake in shares of Lantheus by 259.2% during the second quarter. Mackenzie Financial Corp now owns 15,571 shares of the medical equipment provider’s stock valued at $1,250,000 after acquiring an additional 11,236 shares during the period. Finally, Diker Management LLC bought a new stake in Lantheus during the 2nd quarter worth about $419,000. 99.06% of the stock is owned by institutional investors.

Lantheus Stock Performance

LNTH stock opened at $109.75 on Tuesday. Lantheus Holdings, Inc. has a 1-year low of $50.20 and a 1-year high of $126.89. The business’s 50-day moving average price is $104.36 and its two-hundred day moving average price is $86.40. The firm has a market cap of $7.61 billion, a PE ratio of 16.76 and a beta of 0.50. The company has a current ratio of 4.68, a quick ratio of 4.41 and a debt-to-equity ratio of 0.55.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.68 by ($0.07). The business had revenue of $394.10 million during the quarter, compared to analyst estimates of $382.12 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. Lantheus’s revenue for the quarter was up 22.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.40 earnings per share. As a group, research analysts forecast that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current year.

Insider Transactions at Lantheus

In related news, CAO Andrea Sabens sold 341 shares of the business’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $123.15, for a total value of $41,994.15. Following the sale, the chief accounting officer now directly owns 62,216 shares of the company’s stock, valued at approximately $7,661,900.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Gary J. Pruden sold 12,530 shares of the business’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $95.04, for a total value of $1,190,851.20. Following the sale, the director now owns 11,978 shares of the company’s stock, valued at $1,138,389.12. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CAO Andrea Sabens sold 341 shares of the stock in a transaction on Monday, July 15th. The stock was sold at an average price of $123.15, for a total transaction of $41,994.15. Following the transaction, the chief accounting officer now owns 62,216 shares of the company’s stock, valued at approximately $7,661,900.40. The disclosure for this sale can be found here. Insiders sold 40,852 shares of company stock valued at $3,922,001 over the last quarter. Corporate insiders own 1.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on LNTH. Truist Financial reduced their target price on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a research note on Thursday, August 1st. Redburn Atlantic assumed coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price objective on the stock. JMP Securities dropped their target price on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a research report on Thursday, August 1st. Leerink Partners raised their price target on Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research report on Thursday, July 11th. Finally, B. Riley upped their price objective on Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $126.00.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.